Pleased to share our review on heart failure and obesity published in Nature Reviews Cardiology @NatRevCardiol 🔗 https://t.co/IegmZ46TGM 🔗 https://t.co/AuWub7KgGa Very grateful to my amazing co-authors @LauraMeems DirkvanVeldhuisen NaveedSattar #HeartFailure #HFpEF #Obesity

New online! Heart failure and obesity: novel insights leading to new treatment paradigms https://t.co/LJ29es49Yx

OPERA Study: AI-automated handheld echocardiography🖐️🫀had good diagnostic accuracy for detecting LVEF ≤40% and was interchangeable with cart-based expert human analysis👨‍⚕️🔁🤖 📈 Game-changer for fast, scalable HF diagnosis 🔗 https://t.co/NOQ8xVZ7jC #CardioTwitter #AI

What’s new in #HF June 2025? 🔗 https://t.co/Gx41YNt7x2 💧 Natriuresis & congestion 📡 Remote PAP monitoring 💔 Acute & advanced HF 🧬 Cardio-oncology 🔍 HFmrEF/HFpEF 🩸 IV iron @PauCodi @DaniTomasoni @AlbertoAimo90 @ESC_Journals

What's new in heart failure? April 2025 https://t.co/VHS8IO7UKb #EJHF @ESC_Journals @EJHFEiC

New in CJASN 📢 Our meta-analysis of 66 CKD trials shows both acute & chronic GFR slope independently predict clinical outcomes Findings support 3-year total slope as the optimal surrogate endpoint for CKD trials @asnpublications: https://t.co/wqDIt7B194

Cardiovascular, Kidney & Mortality Outcomes With Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial by @matthewmylee et al. ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD ⬇️ 12% all-cause mortality https://t.co/6yGDiCjDl0

Estimating direct tissue effects versus weight loss effects of #incretin-based drugs for #obesity on various chronic conditions https://t.co/vjdHEUmDtQ #weightloss #GLP-1 receptor agonists

⚖️Direct tissue vs wt loss effects—both matter, but how much?🤔 💉#GLP1RA in #Obesity & chronic conditions: 🩸#T2DM📈#HTN🏥#MACE❤️#HFpEF 🫘#CKD⚠️#MASH💤#OSA🦴#OA 🔗 https://t.co/8e686ndua8 Grateful to Naveed Sattar🙏 #CardioTwitter @TheLancetEndo @MetaMedTeam @UofGSCMH @UofGMVLS

The 2024 top 10 papers in heart failure!!! https://t.co/ZRjH2zplDY #cardiotwitter, @ESC_Journals, @escardio

🗞️ SUGAR-DM-HF #CMR estimated PCWP & congestion markers, and effect of #empagliflozin in #HFrEF with dysglycaemia @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd @HFA_President https://t.co/0zUDx2TPsp

What’s new in #HF Dec 2024? https://t.co/Ylsbds4CQ4 #GDMT in ESC HF III Registry #HFimpEF predictors LV vol & exe capacity in #HFpEF HFpEF in repaired #Coarctation Aorta #CMR #DCMmrEF risk stratificatn #Chagas cardiomyopathy @PauCodi @DaniTomasoni @AlbertoAimo90 @ESC_Journals

EMPRESS-MI: Empagliflozin vs placebo, n=105 w/ LVSD (mean LVEF 34.8%) post-AMI (24wks): ↔️LVESVI, LVEDVI, LVEF, LAVI, LVMI ↔️NT-proBNP, hs-TnI ↗️Hct ↘️urate, weight 🔗 https://t.co/y9H63nVVB0 @CarberryJaclyn @Kieranfdocherty @markcpetrie20 @ColinBerryMD @UoGHeartFailure @UofGSCMH

Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI) treatment with empagliflozin had no effect on cardiac volumes or LVEF https://t.co/BQuxSOu7BG

Ready for #aficamten, a next-in-class myosin inhibitor for oHCM? See the results: https://t.co/vgJH5UnTfO #JACC #cvHCM #SEQUOIA @MartinMaronMD @JJheart_doc @matthewmylee

Excited to share our latest study showing kidney, CV and survival benefits of GLP-1 receptor agonists just published in @TheLancetEndo Time-limited free access https://t.co/skhqzkBvVg 1/

#CVCT2024 : NEW ! Submit your abstract for POSTER PRESENTATIONS → A special French “Wine & Cheese Poster Viewing Session” will be organized just after the keynote lecture on the evening of December 10th, at the peak attendance of CVCT. Find out more here: https://t.co/5zu19JmLbt

Our latest paper summarising evidence for subcutaneous furosemide in heart failure.